CTRI/2021/03/032210尚未招募4 期
Placental vitamin D receptor (VDR) target gene expression in idiopathic fatal growth restriction : a case control study
niversity of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •All pregnant women more than 28 weeks of gestation with USG diagnosed FGR
- •Spontaneous conception
- •Singleton pregnancy
排除标准
- •A. Based oh history and examination
- •Hypertensive disorder of pregnancy, diabetes , chronic hypertension, renal disease , jaundice, epilepsy, multifetal pregnancy , prolonged PROM , SMOKING,ALCOHOL,DRUG abuse, placental abruption
- •B. If any of these investigations are abnormal:
- •OGTT , VDRL, TORCH IgM , Liver function test , Kidney function test, APLA, Fetal anomaly on USG
研究者
相似试验
招募中
不适用
Efficacy of calcitriol therapy in CKD, based on Vitamin D receptor gene polymorphismsCTRI/2020/07/026536Indian Council of Medical Research ICMR
进行中（未招募）
不适用
VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin System Inhibitors - VitalEUCTR2006-001363-31-ITAbbott GmbH & Co KG258
已完成
2 期
Vitamin D receptor polymorphism , vitamin D-fortified Yogurt drink, Type 2 DiabetesType 2 Diabetes.Non-insulin-dependent diabetes mellitusIRCT138810223006N2ational Nutrition & Food Technology Research Institute, Shaheed Beheshti University of Medical Scie120
进行中（未招募）
不适用
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors - Not availableType 2 diabetic nephropathyMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2006-001363-31-DEAbbott GmbH & Co KG258
进行中（未招募）
不适用
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors - Not availableEUCTR2006-001363-31-PTAbbott GmbH & Co KG258